Skip to content
Kineret(anakinra)
Kineret (anakinra) is a protein pharmaceutical. Anakinra was first approved as Kineret on 2001-11-14. It is used to treat cryopyrin-associated periodic syndromes and rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis.
Download report
Favorite
COVID-19
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Kineret
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Anakinra
Tradename
Proper name
Company
Number
Date
Products
KineretanakinraSwedish Orphan Biovitrum AB (publ)N-103950 RX2001-11-14
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
kineretBiologic Licensing Application2020-12-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
cryopyrin-associated periodic syndromesD056587M04.2
rheumatoid arthritisEFO_0000685D001172M06.9
Agency Specific
FDA
EMA
Expiration
Code
anakinra, Kineret, Swedish Orphan Biovitrum AB (publ)
2027-12-18Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L04: Immunosuppressants
L04A: Immunosuppressants
L04AC: Interleukin inhibitors
L04AC03: Anakinra
HCPCS
No data
Clinical
Clinical Trials
166 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Rheumatoid arthritisD001172EFO_0000685M06.9313411
Type 2 diabetes mellitusD003924EFO_0001360E113137
Knee injuriesD0077181112
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382U07.176113
Heart failureD006333EFO_0003144I5027218
Cytokine release syndromeD000080424D89.83425
Mucocutaneous lymph node syndromeD009080EFO_0004246M30.32214
Type 1 diabetes mellitusD003922EFO_0001359E102414
PneumoniaD011014EFO_0003106J18233
Metabolic syndromeD024821EFO_0000195E88.81123
Virus diseasesD014777B34313
Juvenile arthritisD001171EFO_0002609M081113
Chronic renal insufficiencyD051436N18313
Show 19 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InflammationD0072492326
Multiple myelomaD009101C90.0234
Macrophage activation syndromeD055501EFO_1001806134
Chronic kidney failureD007676EFO_0003884N18.6314
B-cell lymphomaD01639333
AsthmaD001249EFO_0000270J45333
Pancreatic neoplasmsD010190EFO_0003860C25213
Large b-cell lymphoma diffuseD016403C83.322
Non-hodgkin lymphomaD008228C85.922
HypoglycemiaD007003HP_0001943E16.2112
Show 36 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients33
NeoplasmsD009369C8022
Cryopyrin-associated periodic syndromesD056587M04.2112
PainD010146EFO_0003843R52112
Breast neoplasmsD001943EFO_0003869C5011
B-cell chronic lymphocytic leukemiaD015451C91.111
Castration-resistant prostatic neoplasmsD06412911
Chronic granulomatous diseaseD006105EFO_0000338D7111
EndometriosisD004715EFO_0001065N8011
Pulmonary arterial hypertensionD00008102911
Show 6 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bariatric surgeryD05011011
Dumping syndromeD004377EFO_1001307K91.111
AdiposityD05015411
Gestational diabetesD016640HP_0009800O24.411
Coronary artery diseaseD003324I25.111
Glucose intoleranceD018149HP_0000833R73.0311
Respiratory insufficiencyD012131HP_0002093J96.911
Conversion disorderD003291F4411
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameANAKINRA
INNanakinra
Description
Interleukin-1 receptor antagonist protein precursor (IL-1ra) (IRAP)
Classification
Protein
Drug classinterleukin receptor antagonists: interleukin-1 (IL-1) receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID143090-92-0
RxCUI72435
ChEMBL IDCHEMBL1201570
ChEBI ID
PubChem CID
DrugBankDB00026
UNII ID9013DUQ28K (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 13,573 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
6,914 adverse events reported
View more details